services, the impact of competitive products and services, the
availability of sufficient quantities of suitable donated tissue and the
success of cost control and margin improvement efforts. Certain of these
factors are detailed from time to time in the Company's periodic reports
filed with the Securities and Exchange Commission. All information in this
press release is as of July 31, 2008 and the Company does not intend to
update this information.
OSTEOTECH, INC. and Subsidiaries
CONSOLIDATED STATEMENTS OF OPERATIONS
(dollars in thousands, except per share data)
Three Months Six Months
Ended June 30, Ended June 30,
2008 2007 2008 2007
Revenue $27,553 $26,470 $55,184 $51,687
Cost of revenue 13,051 13,680 26,440 26,580
Gross profit 14,502 12,790 28,744 25,107
Marketing, selling and
general and
administrative expenses 11,323 10,434 23,003 22,124
Research and development
expenses 1,774 1,281 3,534 2,445
13,097 11,715 26,537 24,569
Operating income 1,405 1,075 2,207 538
Interest expense, net (274) (152) (486) (302)
Other 945 (114) 1,223 22
Income before income taxes 2,076 809 2,944 258
Income tax provision
(benefit) 330 (46) 390 51
Net Income $1,746 $855 $ 2,554 $207
Earnings per share:
Basic
'/>"/>
SOURCE Osteotech, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related medicine news :1.
Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York2.
Osteotech Completes Tissue Supply Agreement With LifeNet Health3.
Osteotech Announces Third Quarter Earnings Release and Conference Call Schedule4.
Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.095.
Osteotech Signs Agreement To Distribute Harvest Technologies BMAC(TM) System6.
Osteotech Engages BioHorizons as Exclusive Distributor to International Dental Market7.
Osteotech Announces the Unexpected Passing of Audit Committee Member Leads to Receipt of Nasdaq Deficiency Letter8.
New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites9.
Haemacure Reports Third Quarter 2007 Results10.
First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion11.
Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best